Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in <i><scp>KRAS</scp></i> wild‐type metastatic colorectal cancer patients: the ObservEr StudyCarmine Pinto, Francesco Di Costanzo, Francesca Di Fabio et al.|Cancer Medicine|2016Cited by 26
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.Emilio Bajetta, Graziella Pinotti, Paolo Bidoli et al.|Journal of Clinical Oncology|2012Cited by 15
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr studyGerardo Rosati, Francesco Di Costanzo, Carmine Pinto et al.|Journal of Geriatric Oncology|2018Cited by 13
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo et al.|Journal of Clinical Oncology|2012Cited by 8
Italian observational study in patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab based regimen (ObservEr study).Francesca Di Fabio, Carmine Pinto, Gerardo Rosati et al.|Journal of Clinical Oncology|2014Cited by 1